Compare Fresenius Kabi Onco. with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ASTRAZENECA PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ASTRAZENECA PHARMA FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.1 101.6 21.8% View Chart
P/BV x 3.1 28.6 10.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA
Mar-18
FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,278 13.8%   
Low Rs79883 8.9%   
Sales per share (Unadj.) Rs37.7228.4 16.5%  
Earnings per share (Unadj.) Rs5.110.4 49.1%  
Cash flow per share (Unadj.) Rs6.716.3 41.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.598.8 43.1%  
Shares outstanding (eoy) m158.2325.00 632.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.7 71.4%   
Avg P/E ratio x25.0104.2 24.0%  
P/CF ratio (eoy) x18.966.4 28.5%  
Price / Book Value ratio x3.010.9 27.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13527,008 74.6%   
No. of employees `0001.21.4 85.0%   
Total wages/salary Rs m7031,535 45.8%   
Avg. sales/employee Rs Th5,176.24,210.9 122.9%   
Avg. wages/employee Rs Th610.41,132.2 53.9%   
Avg. net profit/employee Rs Th699.6191.1 366.1%   
INCOME DATA
Net Sales Rs m5,9635,710 104.4%  
Other income Rs m18123 14.7%   
Total revenues Rs m5,9815,833 102.5%   
Gross profit Rs m1,430463 308.9%  
Depreciation Rs m258147 175.0%   
Interest Rs m-260-   
Profit before tax Rs m1,216438 277.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342179 191.3%   
Profit after tax Rs m806259 311.0%  
Gross profit margin %24.08.1 295.8%  
Effective tax rate %28.140.8 68.9%   
Net profit margin %13.54.5 297.8%  
BALANCE SHEET DATA
Current assets Rs m5,1023,209 159.0%   
Current liabilities Rs m2,3852,070 115.3%   
Net working cap to sales %45.620.0 228.2%  
Current ratio x2.11.6 137.9%  
Inventory Days Days15072 207.4%  
Debtors Days Days11335 324.4%  
Net fixed assets Rs m5,148790 651.4%   
Share capital Rs m15850 316.4%   
"Free" reserves Rs m6,5562,419 271.0%   
Net worth Rs m6,7322,469 272.6%   
Long term debt Rs m9520-   
Total assets Rs m10,3884,605 225.6%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.2 46.3%   
Return on assets %7.55.6 133.4%  
Return on equity %12.010.5 114.1%  
Return on capital %14.617.7 82.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298300 1,768.5%   
Fx outflow Rs m1,7722,015 88.0%   
Net fx Rs m3,525-1,715 -205.5%   
CASH FLOW
From Operations Rs m1,27488 1,449.5%  
From Investments Rs m-1,204-94 1,286.5%  
From Financial Activity Rs m-196NA-  
Net Cashflow Rs m-126-6 2,215.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 9.6 15.7 61.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   42,599 12,856 331.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   DR. DATSONS LABS  BIOCON   J.B.CHEMICALS  JUBILANT LIFE SCIENCES  AJANTA PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Sun Pharma and ITC Top Losers(09:30 am)

Asian stock markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.3%. The Shanghai Composite is trading up by 0.1%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

How We Made 14.64% Trading Profit in Just 2 Days

Dec 12, 2019

A high probability trade that worked to perfection for my subscribers.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

Stocks that Can Outperform No Matter what the RBI Does Today(The 5 Minute Wrapup)

Dec 5, 2019

I won't be surprised if these stocks repeat their 2002-2006 performance.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - DR. REDDYS LAB COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS